Trials / Completed
CompletedNCT01333592
Long-term Study of KAD-1229 in Type 2 Diabetes Patients
A Multicenter, Open Label, Long-term Study of KAD-1229 in Type 2 Diabetes Patients Who Show Inadequate Glycemic Control With Diet, and Biguanide or DPP-4 Inhibitor Monotherapy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- Kissei Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the long-term safety and efficacy of KAD-1229 as combination therapy with biguanide or DPP-4 inhibitor in type 2 diabetes patients who show inadequate glycemic control with diet, and biguanide or DPP-4 inhibitor monotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KAD-1229 |
Timeline
- Primary completion
- 2012-08-01
- Completion
- 2012-11-01
- First posted
- 2011-04-12
- Last updated
- 2014-12-15
- Results posted
- 2014-11-24
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01333592. Inclusion in this directory is not an endorsement.